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Summary This study was performed with the aim of discovering the characteristics and survival of patients
with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen.
One hundred and eighty-one patients with metastatic renal carcinoma were referred to our institute from
October 1987 until August 1991; 129 were treated with Interleukin 2 with or without Interferon alpha in three
successive protocols. Fifty-two patients were not treated with immunotherapy due to the exclusion criteria of
the protocols. Sixty-four patients with the same disease who had been referred to our institute before the
initiation of this programme (1982, 1987) were also analysed as a control group. The main characteristics of
the three different cohorts of patients were analysed and compared with univariate statistical tests; the median
survival of the patients was calculated and compared.
The referral rate increased from 13 a year to 45 a year while the IL2 trials were being conducted.
Patients treated with cytokines have a median survival of 18 months after occurrence of metastases,
compared to 6 and 8 months, respectively, in excluded patients and the control group. This parameter is of 15
months when the 181 patients, treated with cytokines or not, are considered. The survival of treated vs
excluded patients is significantly different (P< 10-6); so is the survival of the 181 patients recently included
when compared to the historical group (P:10 5). When the 181 recent patients are compared to the historical
control group, a number of differences appear in their characteristics, which prevent us from drawing any
conclusion about the role of immunotherapy in the improvement of survival observed.
This study clearly evidences the selection of the patients receiving immunotherapy and the modification in
referrals of a disease induced by a new available therapy. This emphasises the need for prospective studies in
this setting.
Most conventional systemic therapies have little or no acti-
vity in advanced renal carcinoma (Droz et al., 1988; Yagoda
et al., 1989). Immunotherapy with Interferon or Interleukin-2
(IL2), used alone or in combination, has proved to be active
in this disease, leading to response rates ranging from 15 to
30% (Quesada et al., 1983; Krown, 1987; Bergerat et al.,
1988; Rosenberg et al., 1987; 1989a,b; West et al., 1987;
Negrier et al., 1989; 1992; Atzpodien et al., 1990). However,
the toxicity induced by these cytokines is of great concern
and raises the question of the justification of this treatment
modality (Moertel, 1986). According to previous studies, the
median survival time is of 6 to 12 months in patients with
metastatic renal carcinoma (Maldazys et al., 1986; Ritchie et
al., 1987; Forges de et al., 1988; Philip et al., 1989). Very few
consistent data are available yet in the literature concerning
the impact of immunotherapy on survival (Palmer et al.,
1992a). The present study was undertaken first to analyse the
whole cohort of patients accrued during almost 4 years. We
studied their characteristics, prognostic factors as well as
their survival, considering whether they received cytokine
therapy or not. Secondly, we analyse the differences of this
cohort when compared to our historical group.
Patients and methods
Patients and treatments
Three different groups of patients have been defined in this
study; their main characteristics are detailed in Table I. All
therapeutic protocols using unregistered drugs were conduct-
ed after local ethical committee acception and patient in-
formed consent.
Correspondence: T. Philip, Centre L. B&rard, 28 rue Laennec, 69373
Lyon Cedex 08, France.
Received 19 March 1993; and in revised form 12 July 1993.
Almost all patients (at least those included in phase II
trials i.e. 162/181) accrued after initiation of our immuno-
therapy programme, underwent the same investigation proce-
dures to assess eligibility and to screen tumour localisations.
Cranial, thoracic, abdominal and pelvic CT scan, bone scinti-
graphy and blood controls of major organ functions were
performed.
Patients receiving cytotoxic regimens were reevaluated with
at least thoracic and abdominal CT scans combined with
other procedures if necessary.
Includedpatients
One hundred and twenty-nine patients were treated with
cytokines within the immunotherapy programme. Sixty of
these patients received IL2 as a continuous infusion (Euro-
cetus BV Amsterdam, The Netherlands) at 18 x 106 lU/M2/
day, according to the schedule previously reported by West et
al. (1987); LAK cells were associated with IL2 infusion in 22
patients. Thirty-four patients received intravenous IL2 com-
bined with Interferon alpha (IFN) (Schering Plough, Paris,
France) according to the following schedule: one subcuta-
neous injection of IFN at 20 x 106/IU per day for 5 days
then, after a 2-day rest, IL2 as bolus doses at 24 x 106 IU/
m2 q 3/day combined with intravenous IFN at 5 x 106 IU/
m2q 3/day for 5 days. After a 6-day break, during which
cytaphereses were performed in order to develop LAK cells,
the same intravenous combined schedule was carried on for
five additional days along with the LAK cell reinjection.
Twenty-five patients received a combination of subcutaneous
IL2 and IFN according to the schedule of Atzpodien et al.
(1990), previously described. Ten patients, who had received
IFN therapy before being referred to our institute were
treated with a combined therapy of IL2 and Tumor Necrosis
Factor (TNF), as previously reported (Negrier et al., 1992).
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Table I Characteristics .of the three groups of patients
Control Excluded
No. of patients
Age median (range)
Gender (%)
Males
Females
No. patients with initial metastases (%)
Median time between diagnosis and metastases (months)
(If no initial metastasis)
Sites of disease (%)
Lung
Bone
Liver
Brain
Other sites
Local relapse
No. of metastatic sites (%)
<1
2
3
,4
Prior nephrectomy (%)
Adjuvant therapy (%)
No. of systemic therapeutic lines (%)
0
2
3
Radiotherapy (%)
64 52 129
59 (25-80) (59 (36-75) 58 (24-77)
44 (69)
20 (31)
33 (52)
23
41 (64)
40 (63)
4 (6)
5 (8)
40 (62)
9 (14)
23 (36)
31 (48)
9 (14)
1 (1)
46 (71)
12 (19)
31 (48)
23 (36)
10 (16)
0 (0)
44 (69)
40 (77)
12 (23)
36 (69)
19
42
31
9
11
25
5
(81)
(59)
(17)
(21)
(48)
(10)
8 (15)
23 (44)
15 (28)
6 (11)
43 (82)
5 (10)
21(40)
22 (42)
8 (15)
1 (2)
27 (52)
94 (73)
35 (27)
71 (55)
21
110
54
24
6
61
17
(85)
(42)
(19)
(5)
(47)
(13)
34 (26)
58 (45)
33 (26)
4 (3)
113 (88)
8 (6)
0 (0)
60 (46)
44 (34)
25 (20)
53 (41)
Excludedpatients
Between October 1987 and August 1991, 52 (29%) patients
were excluded from immunotherapy because of exclusion
criteria defined in these protocols. Notably, brain metastases
were considered as an exclusion criterion until April 1990.
Patients who were referred after this date, with previously
treated brain metastases (surgery or radiotherapy) without
evidence of evolutive lesions in brain, received IL2 as con-
tinuous infusion. The main reasons of exclusion were respec-
tively: ECOG performance status score under 1 (18), brain
metastases (11), hypercalcemia (5), absence of measurable
tumour lesions (4), refusal (2), ongoing steroid therapy (2),
acute complication due to tumour progression (2), cardiac
failure (1), chronic renal failure (1). We endeavour to give
these patients chemotherapy regimens as phase II therapeutic
trials. Eighteen (35%) were treated with intravenous fotemus-
tine (Servier, Paris, France) (at least three injections separ-
ated by 2 week rest); 15 (29%) received continuous infusion
of FUDR i.e. 5-fluoro-desoxyuracile (Roche, Paris, France)
via an electronic portable pump. Nineteen (36%) received
only palliative support including local radiotherapy.
Controlpatients
Sixty-four patients with metastatic renal cell cancer were
referred to our institute between 1982 and 1987. Their main
characteristics are detailed in Table I. Thirty-three patients
(51%) received systemic therapy (e.g. hormone therapy in 21
and various regimens of chemotherapy in 20) as treatment of
metastatic disease. Five patients only were included in phase
II trials. Sixty-eight percent (44/64) patients received radio-
therapy mainly for pain control and, in 27 (42%) patients
this was the only anticancer treatment performed.
Statistical analysis
The parameters taken into account in the present study,
when available, were those considered in previous reports on
prognostic factors in metastatic renal carcinoma (Forges de
et al., 1988; Elson et al., 1988; Palmer et al., 1992b). Com-
parisons between the different cohorts of patients were per-
formed using the chi-square test for categorical data.
Survival data were evaluated from the date of initial diag-
nosis or of first metastases until the date of death or of last
contact, when the patient is still alive. Survival curves were
calculated using the Kaplan Meier method, and univariate
comparisons between curves were done using the log-rank
test; results are expressed as relative risk (RR).
A multivariate prognosis analysis for survival could not be
performed since some important parameters, i.e. performance
status and weight loss, were not available in the control
group.
Results
Response to treatment
No significant tumour regression was observed in the exclud-
ed patients but five stabilisation of disease for at least 3
months were noted in the patients treated by chemotherapy.
In the 129 treated patients, five complete responses and
16 partial responses (response rate 16%) were achieved and
the details concerning the responding patients are sum-
marised in Table II. All responders but one had previously
undergone nephrectomy, the median number of metastatic
sites was 2 and the median duration of response was 8
months. Stabilisation of the disease was achieved in 42
patients.
No objective tumour regression had been observed within
the historical control group, but ten patients had been con-
sidered as stabilised during at least 3 months.
Comparison between the different groups ofpatients
The main features of the three different cohorts of patients
were compared in an univariate analysis. Table III shows the
results of the comparisons between patients included and
patients excluded from the immunotherapy protocols.
Two parameters that evidence significant differences had
been previously defined as two exclusion criteria of immuno-
therapy protocols. Indeed, patients with brain metastases
were not eligible for the first two protocols. Patients with an
ECOG performance status beneath 1 were ineligible and this
last parameter is dramatically different in the two cohorts (P
value < 10-5). Three other parameters are also significantly
different, the number of patients with bone metastases is
higher within the excluded group, as well as the number of
patients with previous therapy (e.g. chemotherapy or radio-
Included1038 T. PHILIP et al.
Table II Characteristics of responders according to immunotherapy protocols
No. of Response and
Patients and Prior metastatic duration (months)
regimens Gender Age nephrectomy sites
IL2 alone n = 60
1 M 36 + 3 PR (8)
2 M 51 + 2 PR (4)
3 M 50 + 2 PR (21)
4 M 55 + 3 PR (8)
5 M 69 + 3 PR (4)
6 M 75 + 2 CR (24+)
7 M 65 + 1 CR (22+)
8 M 67 + 1 PR (8+)
9 M 34 + 1 PR (9+)
IL2 + IFN HD n =34
1 M 50 + 3 PR (6)
2 M 63 + 2 PR (5)
3 M 63 + 1 CR(12)
4 M 58 + 2 CR (23+)
5 F 60 + 2 PR (4)
6 M 49 + 2 PR (4)
7 M 56 2 PR (CR*) (18+)
8 M 51 + 1 PR (12+)
IL2+IFN LD n=25
1 M 59 + 1 PR (4)
2 M 65 + 2 PR (17+)
3 M 55 + I CR (13)
IL2+TNF n = 10
1 M 60 + 2 PR (4)
*CR post surgery on renal tumour. HD: high doses; LD: low doses; PR: partial
response; CR: complete response.
Table III Comparison of the treated vs excluded patients
P-value
Excluded Treated (chi-square
Parameters (%) (%) test)
Gender (males) 77 73 0.573
No nephrectomy 17 12 0.387
No adjuvant therapy 92 94 0.691
Local relapse 10 13 0.507
No. metastatic sites >2 40 29 0.127T
Brain metastases (yes) 21 5 0.001a
Lung metastases (yes) 81 85 0.455
Liver metastases (yes) 17 19 0.838
Bone metastases (yes) 59 42 0.030a
Other metastatic sites (yes) 49 47 0.923
Patients >65 years at metastases 23 20 0.662
Initial metastases 69 55 0.079T
Previous therapy 37 19 0.008a
chemotherapy 14 1 0.001a
hormonotherapy 2 2 0.868
radiotherapy 31 9 0.0001
Previous stabilisation of disease 20 31 0.141
>4 months
Weight loss > 10% 48 26 0.003a
Performance status ECOG >2 40 11 <10-5
aSignificant P value. T = trend.
therapy) and the number of patients with a weight loss of at
least 10% of their basal weight.
Two additional parameters, thought their P value does not
reach the significant threshold, indicate a difference in these
two populations, i.e. the number of patients with more than
two tumour sites and the number of patients with initial
metastases.
In Table IV, we compared the historical control group vs
the overall cohort of the later patients eligible or not for
immunotherapy. Despite the lack of information for two
major prognostic factors (i.e. weight loss and performance
status), a number of parameters are different in these two
populations. Nephrectomy, lack of adjuvant therapy, lung
and liver metastases are less frequent in the control group as
well as the number of treatments received. In contrast, the
number of patients above 65 at occurrence of metastases is
higher in the control group, and the use of radiotherapy is
more frequent.
In addition, we see a difference in the accrual rate: 13 (64/5
years) patients per year in the control group vs 45 (181/4
years) in the latter group.
Survival analysis
If we consider the survival from the occurrence of metastases,
the median time of follow-up is 37 months (range: 18-71) in
excluded patiens vs 43 months (range: 19-123) in treated
patients. It was 103 months (range 59-150) in the control
group.
According to the survival curves shown in Figure 1, the
median survival time of the control group, of the excluded
group and of the treated group are respectively 8, 6 and 18
months. The difference between the excluded group and
immunotherapy treated patients is significant (RR: 2.28;
P< 10-6) whereas it is not different between the excluded
and the control group (RR: 1.01; P = 0.94). As shown in
Figure 2, excluded patients were pooled together with treated
patients and the median survival time was then of 15 months.
The difference between this population and the control group
remains significant (RR: 1.85; P = 10-5).
When the survival from the date of initial diagnosis is
considered, the median times of follow-up are 43, 37 and 103
months respectively in the immunotherapy, the excluded and
the control groups, with a respective median survival of 24, 9
and 13 months (Figure 3). The survival difference between
the excluded group and the immunotherapy treated patients
is significant (RR: 1.88; P= 10-4). Figure 4 shows the sur-
vival from initial diagnosis of both groups brought together.
The median survival is then of 20 months and remains
significantly different from that of the control group (RR:
1.37; P = 0.02).
Discussion
Even if rigorous criteria, such as WHO criteria for tumour
evaluation are used, the efficacy of immunotherapy with
Interleukin 2 in solid tumours has been judged until now
mainly on the response rates of non randomised phase II
studies (Rosenberg et al., 1987; 1989b; Negrier et al., 1989;
Atzpodien et al., 1990). IL2 induces objective responses inCHARACTERISTICS OF METASTATIC RENAL CARCINOMA 1039
Table IV Comparison of control patients vs prospective cohort
Parameters
Gender (males)
No nephrectomy
No adjuvant therapy
Local relapse
No. of metastatic sites >2
Brain metastases (yes)
Lung metastases (yes)
Liver metastases (yes)
Bone metastases (yes)
Other metastatic sites (yes)
No. patients >65 years at metastases
Initial metastases
No. of systemic lines > 2
(immunotherapy included)
Radiotherapy
aSignificant P value.
Control
- (%)
68
28
81
20
16
5
64
6
56
39
36
51
16
69
Prospective P value
cohort (chi-square
(%) test)
74 0.339
13 O.OlOa
93 0.005a
12 0.109
32 0.01
9 0.237
84 0.001
18 0.021a
47 0.201
47 0.243
21 0.017a
59 0.294
43 0.0007a
44 o.OO1a
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Figure 1 Survival of IL2 treated patients vs excluded vs control group from the occurrence of metastases.
Excluded n = 52; Control group n = 64.
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Figure 2 Survival of the IL2 patients together with excluded patients vs control group from the occurrence of metastases. -------
IL2 + excluded n = 181; Control group n = 64. The survival rate at 18 months was: - IL2 + excluded: 43% (confidence
interval + 8%). - Control: 19% (confidence interval±10%).
only a minority of patients whereas its related toxicity con-
cerns all of them (Siegel et al., 1991). We thus attempted to
analyse the survival and the characterstics of patients with
metastatic renal carcinoma who were referred to our insti-
tute, whether they received immunotherapy or not.
The most conspicuous conclusion that can be drawn from
this study is that patients eligible to receive immunotherapy
are selected. Indeed, 29% of our patients were excluded from
IL2 protocols. This group, as shown by the analysis of their
characteristics and prognostic factors as well as their sur-
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Figure 3 Survival of IL2 treated patients vs excluded vs control group from initial diagnosis.
n = 52; Control group n = 64.
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treated patients together with excluded patients vs control group from initial diagnosis. -------
Control group n = 64. The survival rate at 5 years (60 months) was: - IL2 + excluded: 26%
- Control: 15% (confidence interval± 1O%).
vival, represents a bad prognosis group with a limited sur-
vival (e.g. median survival of 6 months after occurrence of
metastases).
These selection biases lead to an artefactual improvement
of the survival of treated patients when compared to the
overall survival of the population suffering from the same
disease.
Selection of patients is not restricted to this kind of
therapy, but is a common problem in the evaluation of
treatments, specially in oncology (Peto et al., 1976; 1977).
Very few authors, however, mention the exclusion rate of
their clinical trials, but they draw conclusions from a selected
group that are often taken into account for the whole popu-
lation. We thus think that the reports of phase II trials in
oncology should indicate the concomittent exclusion rate.
If we consider patients as a whole, whether treated with
immunotherapy or not, the median overall survival is 16
months after occurrence of metastases. Since the literature
reports no series with a median survival time over 1 year, we
attempted to appreciate the factors that could be responsible
for this improvement. With this aim, we analysed our histor-
ical control group, i.e. patients referred to our institute dur-
ing the 5 years preceding initiation of the immunotherapy
programme, in which the median survival is of 8 months.
Such a median survival of 8 months has also been reported
in another cohort of French patients with the same disease
receiving different regimens of chemotherapy as phase II
trials (Forges de et al., 1988). Our results were weakened by
the lack of two important prognostic factors which were not
available in the retrospective cohort; i.e., weight loss and
performance status.
Performance status appeared in three previous studies as a
very powerful prognostic factor (de Forges, 1988; Elson
1988; Palmer, 1992b). Therefore, matching the patients on
other available characteristics was judged as not suitable.
Despite the fact that these two prognostic factors, i.e.
weightloss and performance status, were not available in the
retrospective series, the analysis of this group and the com-
parison with the latter group show a number of differences
that correspond to selection biases. First of all, the accrual
rate is quite different, i.e. 13 patients/year vs 45, which proves
that referrals of this disease are very much stimulated by
available therapy. Notably, drawn from the incidence rate of
this disease and the number of inhabitants in the surrounding
area, we estimated that approximately half the patients
suffering from metastatic renal cancer were currently referred
to our institution.
In addition, three parameters that are significantly different
could partially explain the difference in survival, indepen-
dently from the receiving of immunotherapy. Though median
ages are identical, there are more patients over 65 with
occurrence of metastases and, in addition, a greater number
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of patients who did not undergo nephrectomy within the
control group. Control patients received fewer systemic
therapeutic lines than the immunotherapy treated patients,
and this parameter might influence their survival as well.
Conversely, we note that the number of control patients
with more than two tumour sites is reduced, as well as the
number of patients with lung and liver metastases. This
difference in the number of metastatic sites would indicate
that, despite a larger tumour burden, the survival of patients
treated recently has been significantly improved. We must,
however, point out that this last parameter should be con-
sidered with caution since the detection of metastatic sites
was very different in these two cohorts. In fact, in the control
group, metastatic lesions were merely detected when they
became symptomatic, whereas a complete initial screening
was performed in almost all the patients belonging to the
second cohort, i.e. at least all patients in phase II trials
(162/181: 89%). For this reason, the bulk of the disease was
probably underestimated in our historical group.
As a result of selection bias and lead time bias, the two
populations are obviously different. For this reason, it is not
possible to appreciate the role of immunotherapy in the
improved survival observed in recent patients. Notably, the
starting point of survival evaluation, i.e. initial diagnosis vs
first metastases, does not influence the results of our study,
but reduced the difference in survival. Indeed, the survival of
the control group appeared somewhat more favourable when
analysed from initial diagnosis, whereas the shape of the
curve is not modified in the prospective group. We hypothe-
tised that the diagnosis of metastases has been done later in
the course of the disease in the control than in the prospec-
tive group.
This analysis emphasises the impact of a new specific
therapeutic programme and the management or follow-up
modifications induced by the close evaluation of controlled
trials (Osband et al., 1990).
As a consequence, survival evaluation, especially for
immunotherapy in metastatic renal cancer, is difficult. The
most logical and objective way to appreciate the real impact
of immunotherapy on survival would be to compare, within
a prospective randomised trial, a treated group vs a placebo
group. This situation, however, is ethically unfair since we
know that immunotherapy can bring, although in only some
patients, durable complete remissions.
Therefore, we now have to appreciate the response rate
and survival of patients treated with different cytokine
schedules in prospective multicentric trials and to try and
evidence the predictive factors of response to therapy. Such a
study is presently ongoing in France in metastatic renal
carcinoma.
In summary, this study shows that the administration of
immunotherapy with cytokines results in a selection of
patients with the exclusion of a poor survival group. There-
fore, the exclusion rate should also be investigated and
reported in phase II trials in this setting. It also demonstrates
the impact of a new therapeutic modality on referrals of a
disease. The survival of patients with metastatic renal car-
cinoma treated with immunotherapy remains to be inves-
tigated specifically in a prospective and comparative setting.
This work was supported by the Ligue Nationale contre le Cancer.
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